Abstract Purpose of Review: This article discusses the recent advances in the diagnosis and
treatment of Alzheimer disease (AD). Recent Findings: In recent years, significant advances …

Intense multidisciplinary research has provided detailed knowledge of the molecular
pathogenesis of Alzheimer disease (AD). This knowledge has been translated into new …

Some forms of mild cognitive impairment (MCI) are the clinical precursors of Alzheimer's
disease (AD), while other MCI types tend to remain stable over-time and do not progress to …

Context Early detection of prodromal Alzheimer disease (AD) is important because new
disease-modifying therapies are most likely to be effective when initiated during the early …

Context Small single-center studies have shown that cerebrospinal fluid (CSF) biomarkers
may be useful to identify incipient Alzheimer disease (AD) in patients with mild cognitive …

Early diagnosis of Alzheimer's disease (AD) is needed to initiate symptomatic treatment with
acetylcholinesterase inhibitors, and will be of even greater significance if drugs aimed at …

The recent failures of potential disease-modifying drugs for Alzheimer's disease (AD) may
reflect the fact that the enrolled participants in clinical trials are already too advanced to …

Background Alzheimer's disease (AD) pathology is common in patients with amnestic mild
cognitive impairment (aMCI) without dementia, but the prevalence of AD pathology in …

Background We aimed to identify the most useful definition of the “cerebrospinal fluid
Alzheimer profile,” based on amyloid-ß 1-42 (Aβ 42), total tau, and phosphorylated tau (p …

The introduction of acetylcholine esterase (AChE) inhibitors as a symptomatic treatment of
Alzheimer's disease (AD) has made patients seek medical advice at an earlier stage of the …